



MediPen® Expand Access To A Range Of Non-Psychoactive Cannabinoids

Creators are confident that the introduction of more cannabinoids to the consumer market will bring them closer to their goal of making medicinal cannabis readily available in the United Kingdom.

The UK's leading consumer cannabis biotechnology company have introduced two additional non-psychoactive cannabinoids, Cannabidivarin (CBDV) and Cannabigerol (CBG), to their globally recognized proprietary cannabinoid formulation.

Cannabidivarin (CBDV) and Cannabigerol (CBG) currently have no medicinal regulatory status assigned within the UK however there are numerous peer-reviewed scientific studies that demonstrate analgesic and anti-inflammatory properties along with promising antidepressant and anxiolytic effects. These cannabinoids have also been found to harmonise with other cannabinoids such as Cannabidiol (CBD) and Delta9-Tetrahydrocannabinol (THC) to promote a heightened sense of therapeutic synergy.

Following a long period of research and development after sourcing the new cannabinoids from a cutting edge hybrid strain of the cannabis plant, MediPen® have successfully integrated Cannabidivarin (CBDV) and Cannabigerol (CBG) into their world renowned Cannabidiol (CBD) formulation.

The MediPen® Cannabinoid Vaporizer is completely legal in the UK as it does not contain any traces of controlled compounds and does not induce any of the psychoactive effects associated with traditional cannabis use.

You can find out more and purchase a MediPen® Starter Kit directly from their website today
<https://medipen.co>

[1] Colasanti BK, et al. Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol. *Exp Eye Res.* 1984 Sep;39(3):251-9.

[2] Colasanti BK. A Comparison of the Ocular and Central Effects of $\Delta 9$ -Tetrahydrocannabinol and Cannabigerol. *Journal of Ocular Pharmacology and Therapeutics.* March 2009, 6(4): 259-269. doi:10.1089/jop.1990.6.259.

[3] Borrelli F, et al. Beneficial effect of the non-psychoactive plant cannabinoid cannabigerol on experimental inflammatory bowel disease. *Biochemical Pharmacology, Volume 85, Issue 9, 1 May 2013, Pages 1306–1316.*

[4] Williamson EM, Evans FJ. Cannabinoids in clinical practice. *Drugs.* 2000 Dec;60(6):1303-14.

[5] Cascio MG, et al. Evidence that the plant cannabinoid cannabigerol is a highly potent $\alpha 2$ -adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. *Br J Pharmacol.* 2010 Jan; 159(1): 129–141.

[6] El-Alfy AT, et al. Antidepressant-like effect of $\Delta 9$ -tetrahydrocannabinol and other cannabinoids isolated from *Cannabis sativa L.* *Pharmacol Biochem Behav.* 2010 Jun; 95(4): 434–442.

[7] Rock EM, et al. Interaction between non-psychoactive cannabinoids in marijuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. *Psychopharmacology (Berl).* 2011 Jun;215(3):505-12.

[8] Borrelli F, et al. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychoactive cannabinoid. *Carcinogenesis.* 2014 Dec;35(12):2787-97.

[9] Petrocellis LD, et al. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. *Br J Pharmacol.* 2013 Jan; 168(1): 79–102.

[10] Jun'ichi N, et al. Structure-dependent inhibitory effects of synthetic cannabinoids against 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and skin tumour promotion in mice. *JPP Journal of Pharmacy and Pharmacology.* Volume 65, Issue 8, August 2013, Pages 1223–1230.

- [11] Seung-Hwa B, et al. Synthesis and antitumor activity of cannabigerol. *Archives of Pharmacal Research*. June 1996, Volume 19, Issue 3, pp 228–230.
- [12] Russo E. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *British Journal of Pharmacology*, 2010, 1348. <http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2011.01238.x/pdf>
- [13] Hill AJ, et al. Phytocannabinoids as novel therapeutic agents in CNS disorders. *Pharmacol Ther*. 2012 Jan;133(1):79-97.
- [14] Valdeolivas S, et al. Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. *Neurotherapeutics*. 2015 Jan;12(1):185-99.
- [15] Aitor GG, et al. A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis. *Journal of Neuroimmune Pharmacology*. December 2012, Volume 7, Issue 4, pp 1002–1016.
- [16] Deiana S, et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarin (CBDV), Δ^9 -tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviour. *Psychopharmacology*. February 2012, Volume 219, Issue 3, pp 859–873.
- [17] Elsohly HN, et al. Synthesis and Antimicrobial Activities of Certain Cannabichromene and Cannabigerol Related Compounds. *Journal of Pharmaceutical Sciences*. Volume 71, Issue 12, December 1982, Pages 1319-1323.
- [18] Appendino G, et al. Antibacterial cannabinoids from *Cannabis sativa*: a structure–activity study. *J Nat Prod*. 2008 Aug;71(8):1427-30.
- [19] Wilkinson JD, Williamson EM. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. *J Dermatol Sci*. 2007 Feb;45(2):87-92.
- [20] Pagano E, et al. Effect of Non-psychotropic Plant-derived Cannabinoids on Bladder Contractility: focus on Cannabigerol. *Natural Product Communications* [2015, 10(6):1009-1012].